Randomized trial · people

Semaglutide 7.2 mg: 18.7% weight loss at 72 weeks in STEP UP

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this trial, the 7.2 mg dose brought 3.1% more weight loss than 2.4 mg over 72 weeks, along with more gut side effects and more frequent skin-sensation side effects.

Kind
Randomized trial
Studied in
People
Number studied
1407
Published
2025
Journal
Lancet Diabetes Endocrinol

What they tested

The team tested whether a higher weekly dose of semaglutide, 7.2 mg, leads to more weight loss than placebo and the 2.4 mg dose in adults with obesity, and how safe it is.

How the study was done

A randomized, double-blind trial in 1407 adults with a BMI of 30 kg/m2 or more and no diabetes, at 95 sites in 11 countries. For 72 weeks they got weekly injections of semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo (a dummy shot), all alongside a lifestyle program.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Body weight fell by 18.7% in the 7.2 mg arm, 15.6% in the 2.4 mg arm and 3.9% in the placebo arm, putting 7.2 mg ahead of 2.4 mg by 3.1% and ahead of placebo by 14.8%. People on 7.2 mg were more likely than those on 2.4 mg to lose 20% or more of their weight (odds ratio 1.8) and 25% or more (odds ratio 2.4), and waist size shrank by 11.7 cm more than with placebo. Gut side effects hit 70.8% on 7.2 mg, 61.2% on 2.4 mg and 42.8% on placebo, and dysesthesia (odd or unpleasant skin sensations) hit 22.9%, 6.0% and 0.5%. Serious adverse events occurred in 6.8%, 10.9% and 5.5%, and the authors judged the 7.2 mg dose's risk-benefit balance favorable.

What it doesn’t show

The trial lasted 72 weeks and left out people with diabetes. Its 2.4 mg and placebo arms were much smaller than the 7.2 mg arm, and 73.7% of participants were female. It was funded by Novo Nordisk.

The paper

Wharton et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025.

The compound

More studies on Semaglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo